Lipid Profile and Hepatic Steatosis in Hepatitis C Infected Egyptian Survivors of Childhood Cancer

REFERENCES

• Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436–2441.
   PubMed Web of Science ®Google Scholar
• El-Zanaty F, Way A. Egypt: Demographic and Health Survey (DHS). Cairo: Ministry of Health. http://www.measuredhs.com/pubs/pdf/FR220/FR220.pdf
   Google Scholar
• Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–538.
   PubMed Web of Science ®Google Scholar
• El-Sayed MH, Mohamed MM, Karim A, et al. Severe liver disease is caused by HBV rather than HCV in children with hematological malignancies. Hematol J. 2003;4:321–327.
   Google Scholar
• Said ZN, El-Sayed MH, El-Bishbishi IA, et al. High prevalence of occult hepatitis B in hepatitis C-infected Egyptian children with haematological disorders and malignancies. Liver Int. 2009;29(4):518–524.
   Google Scholar
• Moriya K, Shintani Y, Fujie H, et al. Serum lipid profile of patients with genotype 1b hepatitis C viral infection in Japan. Hepatol Res. 2003;25(4):371–376.
   Google Scholar
• Petit JM, Benichou M, Duvillard L, et al. Hepatitis C virus-associated is correlated with hypobetalipoproteinemia plasma viral load, steatosis, and liver fibrosis. Am J Gastroenterol. 2003;98(5): 1150–1154.
   Web of Science ®Google Scholar
• Sheridan DA, Price DA, Schmid ML, et al. Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving antiviral agents interferon-alpha and ribavirin. Aliment Pharmacol Ther. 2009;29(12):1282–1290.
   PubMed Web of Science ®Google Scholar
• Corey KE, Kane E, Munroe C, et al. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology. 2009;50(4):1030–1037.
   PubMed Web of Science ®Google Scholar
• Fernadez-Rodriguez CM, Lopez-Serrano P, Alonso S, et al. Long-term reversal of hypocholesterolaemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype. Aliment Pharmacol Ther. 2006;24(3):507–512.
   Google Scholar
• Mostafa A, Mohamed MK, Saeed M, et al. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut. 2010;59(8):1135–1140.
   PubMed Web of Science ®Google Scholar
• Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Semin Liver Disease. 1995;15(1):70–81.
   Google Scholar
• Czaja AJ, Carpenter HA, Santrach PJ, et al. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol. 1998;29(2):198–206.
   PubMed Web of Science ®Google Scholar
• Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130(6): 1636–1642.
   PubMed Web of Science ®Google Scholar
• Hu KQ, Currie SL, Shen H, et al. Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans. Dig Dis Sci. 2007;52(2):570–578.
   Google Scholar
• Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alpha-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38(1):75–85.
   PubMed Web of Science ®Google Scholar
• Kamal SM, Nasser IE. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology. 2008;47(4):1371–1383.
   PubMed Web of Science ®Google Scholar
• Figlerowicz M, Sluzewski W, Kowala-Piaskowska A, et al. Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C. Eur J Pediatr. 2004;163(4–5):265–267.
   Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
   PubMed Web of Science ®Google Scholar
• Bray GA. Pathophysiology of obesity. Am J Clin Nutr. 1992;55:488S–494S.
   PubMed Web of Science ®Google Scholar
• Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21:3–16.
   PubMed Web of Science ®Google Scholar
• Lao XQ, Thompson A, McHutchison JG, et al. Sex and age differences in lipid response to chronic infection with the hepatitis C virus in the United States National Health and Nutrition Examination Surveys. J Viral Hepat. 2011;18(8):571–579.
   Google Scholar
• Miyazaki T, Honda A, Ikegami T, et al. Hepatitis C virus infection causes hypolipidemia regardless of hepatic damage or nutritional state: an epidemiological survey of a large Japanese cohort. Hepatol Res. 2011;41(6):530–541.
   Google Scholar
• Wiśniewska-Ligier M, Konopka A, Woźniakowska-Gęsicka T. Lipid and carbohydrate parameters in children with chronic hepatitis C. Adv Med Sci. 2011;56(2):180–185.
   Google Scholar
• Wisniewska-Ligier M, Wozniakowska-Gesicka T, Kups J, et al. Lipid metabolism in children with chronic hepatitis C, A preliminary report. Hepatogastroenterology. 2006;53(72):887–891.
   Google Scholar
• Kozłowski P, Pogorzelska J, Łapiński TW, et al. The occurrence of HCV genotypes and single polynucleotide polymorphisms of rs12979860 among HCV infected patients in northeastern Poland. Przegl Epidemiol. 2012;66(2):335–339.
   Google Scholar
• Khattab MA, Eslam M, Aly MM, et al. Serum lipids and chronic hepatitis C genotype 4: interaction and significance. Ann Hepatol. 2012;11(1):37–46.
   PubMed Web of Science ®Google Scholar
• Ouakaa-Kchaou A, Gargouri D, Kochlef A, et al. Steatosis in chronic hepatitis C: prevalence and predictive factors. Tunis Med. 2011;89(11):830–836.
   Google Scholar
• Ahmed AM, Hassan MS, Abd-Elsayed A, et al. Insulin resistance, steatosis, and fibrosis in Egyptian patients with chronic hepatitis C virus infection. Saudi J Gastroenterol. 2011;17(4):245–251.
   Google Scholar
• Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol. 2000;33:106–115.
   PubMed Web of Science ®Google Scholar
• Gordon A, McLean CA, Pedersen JS, et al. Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. J Hepatol. 2005;43:38–44.
   Google Scholar
• Goodman ZD, Makhlouf HR, Liu L, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C trial. Hepatology. 2008;47(3):836–843.
   PubMed Web of Science ®Google Scholar
• Fu CC, Chen MC, Li YM, et al. The risk factors for ultrasound-diagnosed non-alcoholic fatty liver disease among adolescents. Ann Acad Med Singapore. 2009;38(1):15–17.
   Google Scholar
• Petta S, Amato M, Cabibi D, et al. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology. 2010;52(5):1543–1552.
   PubMed Web of Science ®Google Scholar
• Delgado-Borrego A, Healey D, Negre B, et al. Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr. 2010;51(2):191–197.
   Web of Science ®Google Scholar
• Cross TJ, Quaglia A, Nolan J, et al. Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection? J Med Virol. 2010;82(6):958–964.
   Google Scholar
• Rodriguez-Torres M, Govindarajan S, Diago M, et al. Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks. Liver Int. 2009;29(2):237–241.
   Google Scholar
• Negro F, Sanyal AJ. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int. 2009;29(Suppl 2):26–37.
   PubMedGoogle Scholar
• Delgado-Borrego A, Healey D, Negre B, et al. Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr. 2010;51(2):191–197.
   Web of Science ®Google Scholar
• Moriya K, Shintani Y, Fujie H, et al. Serum lipid profile of patients with genotype 1b hepatitis C viral infection in Japan. Hepatol Res. 2003;25(4):371–376.
   Google Scholar
• Petit JM, Benichou M, Duvillard L, et al. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am J Gastroenterol. 2003;98(5):1150–1115.
   PubMed Web of Science ®Google Scholar
• Domitrovich AM, Felmlee DJ, Siddiqui A. Hepatitis C virus nonstructural proteins inhibit apolipoprotein B100 secretion. J Biol Chem. 2005;280(48):39802–39808.
   Google Scholar
• Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38(1):75–85.
   PubMed Web of Science ®Google Scholar
• Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol. 2004;40(3):484–490.
   PubMed Web of Science ®Google Scholar
• Westin J, Lagging M, Dhillon AP, et al. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepatitis. 2007;14(1):29–35.
   Google Scholar
• Lok AS, Everhart JE, Chung RT, et al. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol. 2007;5(2):245–254.
   Google Scholar
• Shah SR, Patel K, Marcellin P, et al. Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. Clin Gastroenterol Hepatol. 2011;9(8):688–693.
   PubMed Web of Science ®Google Scholar
• Thomopoulos KC, Theocharis GJ, Tsamantas AC, et al. Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol. 2005;17(2):149–153.
   Google Scholar
• Fabris P, Floreani A, Carlotto A, et al. Impact of liver steatosis on virological response in [corrected] Italian patients with chronic hepatitis C treated with peg-interferon alpha-2b plus ribavarin. Aliment Pharmacol Ther. 2005;21:1173–1178.
   Google Scholar